logo
Share SHARE
FONT-SIZE Plus   Neg

Abiomed Obtains FDA 510(k) Clearance For New Impella Percutaneous Heart Pump

Abiomed Inc. (ABMD), a provider of breakthrough heart support technologies, announced it has received 510(k) clearance from the U.S. Food and Drug Administration or FDA for a new percutaneous, catheter-based Impella device providing peak flows of approximately four liters of blood per minute.
The company stated that the increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5. This new heart pump will be marketed as the Impella CP (Cardiac Power) within the United States and has been commercially known outside the U.S. as the Impella cVAD.

This 510(k) clearance designated that the Impella CP has the same indications for use as the Impella 2.5 and includes a limitation in the Impella CP instructions for use or IFU, the company said.

In April 2012, Abiomed received CE Marking approval to market the Impella cVAD in the European Union.

Abiomed said it plans to have a controlled launch with top heart hospitals in the United States, with full U.S. commercial availability of the Impella CP expected by the fourth quarter of fiscal 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Elon Musk's space transport company SpaceX has lost a satellite launch order from one of its customers due to the delay in its rocket launch schedule after one of its rockets exploded in September. Free meals in coach might soon make a comeback on Delta Air Lines Inc. The Atlanta-based airline said it is testing complimentary meals in the main cabin on transcontinental flights between JFK International Airport in New York and Los Angeles International Airport or San Francisco International Airport. Air Canada plans to add three U.S. routes next year, to cities San Antonio, Memphis and Savannah, the airline announced. The company said it will launch six new non-stop U.S. services beginning Spring 2017.
comments powered by Disqus
Follow RTT